A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)

被引：0
|
作者：
Shen, Lin
Yu, Xianjun
Hao, Jihui
Wang, Liwei
Pan, Hongming
Han, Guohong
Xu, Jian-Ming
Zhang, Yanqiao
Yang, Shujun
Chen, Jia
Ying, Jieer
Dai, Guanghai
Li, Mingyu
Begic, Damir
Lu, Brian D.
Xu, Ruihua
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
[3] Tianjin Canc Hosp, Tianjin, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
[5] Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China
[6] Fourth Mil Med Univ, Dept Liver Dis & Digest Intervent Radiol, Xijing Hosp Digest Dis, Xian 710032, Peoples R China
[7] Acad Mil Med Sci, Hosp 307, Ctr Canc, Beijing, Peoples R China
[8] Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
[9] Henan Canc Hosp, Zhengzhou, Peoples R China
[10] Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
[11] Zhejiang Canc Hosp, Dept Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[12] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[13] Celgene Corp, Summit, NJ USA
[14] Celgene Corp, Madison, NJ USA
[15] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.327
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
327
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase Ib of anticancer stem cell antibody OMP-59R5 (anti-Notch2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)
    O'Reilly, Eileen Mary
    Smith, Lon S.
    Bendell, Johanna C.
    Rangwala, Fatima A.
    Schmidt, William
    Stephenson, Joe
    Kapoun, Ann
    Xu, Lu
    Hill, Dawn
    Zhou, Lei
    Dupont, Jakob
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] Impact of nab-paclitaxel (nab-P) plus gemcitabine (G) vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer.
    Chiorean, E. Gabriela
    Wan, Yin
    Whiting, Scott
    Kayitalire, Louis
    Botteman, Marc
    Ji, Xiang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Efficacy and safety of nab-paclitaxel (nab-P) in patients (pts) with previously treated metastatic colorectal cancer (mCRC): The phase II COLO-001 trial
    Ducreux, M.
    Bennouna, J.
    Adenis, A.
    Conroy, T.
    Lievre, A.
    Portales, F.
    McGovern, D.
    Li, L.
    Romano, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S376 - S376
  • [44] The international, open-label, multicenter phase 2 LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) for patients with locally advanced pancreatic cancer (LAPC)
    Pascal, Hammel
    Jill, Lacy
    Fabienne, Portales
    Alberto, Sobrero
    Beatriz, Garca-Paredes
    Edward, Kim
    Fernando, Rivera
    Jose Luis, Manzano
    Eric, Terrebonne
    Venu, Bathini
    Scot, Dowden
    Jamil, Asselah
    Jack, Shiansong Li
    Thomas, Nydam
    Louis, Kayitalire
    Philip, Philip
    ANNALS OF ONCOLOGY, 2016, 27 : 78 - 79
  • [45] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [46] Efficacy and safety of nab-paclitaxel plus S-1(nab-P/S-1) versus nab-paclitaxel plus gemcitabine (nab-P/Gem) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A randomized study
    Zong, Yuan
    Peng, Zhi
    Wang, Xicheng
    Shen, Lin
    Zhou, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [47] Phase I study of nivolumab (nivo) plus nab-paclitaxel (nab-P) ± gemcitabine (Gem) in solid tumors: Interim results from the pancreatic cancer (PC) cohorts.
    Wainberg, Zev A.
    Hochster, Howard S.
    George, Ben
    Gutierrez, Martin
    Johns, Mark Emery
    Chiorean, E. Gabriela
    Kwak, Eunice Lee
    Kalyan, Aparna
    Manax, Victoria
    Ye, Moncy
    Chen, Tianlei
    Trunova, Nataliya
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [48] Efficacy, Safety and Pharmacokinetics (PK) of Weekly nab-paclitaxel (P) Plus Gemcitabine (G) in Japanese Patients (pts) With Metastatic Pancreatic Cancer (MPC): Phase I/II Trial
    Kasuga, A.
    Ueno, H.
    Ikeda, M.
    Ueno, M.
    Mizuno, N.
    Ioka, T.
    Omuro, Y.
    Nakajima, T. E.
    Furuse, J.
    PANCREAS, 2014, 43 (08) : 1374 - 1374
  • [49] A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC).
    Ko, Andrew H.
    Murray, James
    Horgan, Kerry E.
    Dauer, Julia
    Curley, Michael
    Baum, Jason
    Louis, Chrystal Ursula
    Lugovskoy, Alexey
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [50] A pilot phase II multicenter study of nab-paclitaxel (Nab-P) and gemcitabine (G) as preoperative therapy for potentially resectable pancreatic cancer (PC)
    MacKenzie, Shawn
    Zeh, Herbert
    McCahill, Laurence E.
    Sielaff, Timothy D.
    Bahary, Nathan
    Gribbin, Thomas Edward
    Seng, John E.
    Leach, Joseph W.
    Harmon, Jocelyn
    Demeure, Michael J.
    Von Hoff, Daniel D.
    Moser, A. Jim
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345